Alpha IVF Group (0303) Fair Value & Analysis
Healthcare · MY · Market cap 1.2B MYR
Fair value as of: Jul 16, 2026
From 26 valuation models · updated 25 days ago
Share price +10.0% over the past month.
A solid business, but screening 24% overvalued on our models.
What matters now
- A high-quality business (quality 72/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety.
- Our model range runs from 0.1600 MYR (bear) to 0.2700 MYR (bull), base 0.2100 MYR. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 72/100 (solid quality) with high evidence: the data supports the verdict.
Price vs Fair Value (2 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 16, 2026.
How to read this chart
29‑month range 0.2400 MYR – 0.3470 MYR · fair‑value band 0.1600 MYR – 0.2700 MYR · the 0.2750 MYR price screens above the 0.2100 MYR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 16, 2026.
Analysis
Alpha IVF Group (0303) currently trades at 0.2750 MYR, while our model-based Fair Value estimate is 0.2100 MYR, implying the stock looks roughly 23.6% overvalued today. The Quality Score stands at 72/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Alpha IVF Group generated revenue of 197M MYR at a net margin of 28.4%. Revenue grew 16.1% year over year. It earns a return on equity of 29.6%. Net debt stands at 6.2M MYR. Fundamentals as of Jul 16, 2026
Our scenario range runs from 0.1600 MYR (bear case) to 0.2700 MYR (bull case); at 0.2750 MYR, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 19% below its 52-week high and 17% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 11% fair-value upside, at -24%, 0303 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Growth Earnings (0.3400 MYR) versus Asset-Based (0.0300 MYR). Highest evidence: Growth DCF (80).
Notify me when 0303 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 16, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 73 · Market factors (momentum, volatility) 53
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Alpha IVF Group Berhad, together with its subsidiaries, operates as a fertility care specialist that focuses on the provision of assisted reproductive services in Malaysia, Singapore, Indonesia, China, Middle East, the Philippines, and internationally.
Full company description
Alpha IVF Group Berhad, together with its subsidiaries, operates as a fertility care specialist that focuses on the provision of assisted reproductive services in Malaysia, Singapore, Indonesia, China, Middle East, the Philippines, and internationally. The company offers assisted reproductive treatment services comprising ovulation induction, intra-uterine insemination, in-vitro fertilization treatment, intra-cytoplasmic sperm injection, gamete intrafallopian transfer, and savior sibling program; preimplantation genetic testing; implantation optimisation; sperm sorting; and egg freezing, embryo freezing and cryo-storage, laparoscopic surgery, hysteroscopic surgery, 4D ultrasound scanning, and artificial intelligence-enhanced embryo selection services. It also provides various diagnostics, testing and screening procedures; cryopreservation of eggs and sperms; medical consultants; fertility, gynecological, and obstetric treatment; and other women-related healthcare and medical services. In addition, the company operates women's specialist centers. Alpha IVF Group Berhad was founded in 2011 and is based in Petaling Jaya, Malaysia.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Alpha IVF Group reported revenue of 177M MYR in FY2025 versus 62.1M MYR in FY2021, a compound +29.9%/yr. Reported net income was 57.5M MYR in FY2025.
0303 screens 24% overvalued. Compare with HCA Healthcare, Inc →
Peer Group
Medical Care Facilities · 261 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 35/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 16, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $378.85 | $554.93 | +46% |
| Fresenius SE FRE | €41.73 | €32.15 | -23% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.58 SGD | 1.44 SGD | -44% |
| Tenet Healthcare Corporation THC | $194.91 | $338.05 | +73% |
| Rede D'Or São Luiz S.A RDOR3 | R$36.01 | R$47.31 | +31% |
| DaVita Inc DVA | $231.61 | $255.97 | +11% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,955 | ₹2,955 | -67% |
| Fresenius Medical Care AG FMS | $24.68 | $45.60 | +85% |
| Aier Eye Hospital Group 300015 | ¥8.68 | ¥7.67 | -12% |
Compare Alpha IVF Group with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Alpha IVF Group (0303) overvalued or undervalued?
What is the fair value of 0303?
What is the quality score of 0303?
What is the revenue of Alpha IVF Group (0303)?
What is the net profit margin of 0303?
Does Alpha IVF Group pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Alpha IVF Group and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.